On February 12, 2026, Immunic, Inc. entered a securities purchase agreement to raise approximately $200 million through a private placement of pre-funded and common warrants, with a closing date expected around February 17, 2026. The company also announced a reverse stock split of at least 10:1 and appointed Thor Nagel to its board, while Maria Törnsén resigned.